Who are the top shareholders of the Astrazeneca Phar?

The top shareholders of Astrazeneca Phar include Astrazeneca Pharmaceuticals Ab with 75.0%, Nippon Life India Trustee Ltd at 2.92%, mutual funds holding 4.45%, foreign institutional investors at 2.89%, and individual investors with 15.16%.

The top shareholders of Astrazeneca Phar include Astrazeneca Pharmaceuticals Ab, which holds a significant 75.0% of the shares. Other notable shareholders are Nippon Life India Trustee Ltd, representing the Nippon India Small Cap Fund across various schemes, with a holding of 2.92%. Additionally, mutual funds collectively hold 4.45% through 53 schemes, and foreign institutional investors (FIIs) own 2.89% across 95 entities. Individual investors also have a notable presence, holding 15.16% of the shares.

Who are in the management team of Astrazeneca Phar?

As of March 2023, the management team of Astrazeneca Phar includes Narayan K Seshadri (Chairman), Rajesh Marwaha (CFO), Sanjeev Panchal (Managing Director), and several non-executive and independent directors. Key members also include Revathy Ashok, Weiying Sarah Wang, Ankush Nandra, Shilpa Divekar Nirula, and Hooi Bien Chuah.

As of March 2023, the management team of Astrazeneca Phar includes the following members:<BR><BR>1. Narayan K Seshadri - Chairman & Independent Director<BR>2. Revathy Ashok - Non-Executive & Independent Director<BR>3. Rajesh Marwaha - Whole Time Director & CFO<BR>4. Weiying Sarah Wang - Non-Executive Director<BR>5. Ankush Nandra - Non-Executive Director<BR>6. Shilpa Divekar Nirula - Non-Executive & Independent Director<BR>7. Sanjeev Panchal - Managing Director<BR>8. Hooi Bien Chuah - Non-Executive Director<BR><BR>These individuals play key roles in the governance and management of the company.

When is the next results date for Astrazeneca Phar?

No Upcoming Board Meetings

Has Astrazeneca Phar declared dividend?

Astrazeneca Pharma India Ltd has declared a 1200% dividend, amounting to ₹24 per share, with an ex-date of July 5, 2024. The company has shown strong price appreciation over various periods, with total returns of up to 233.77% over three years, despite low dividend yields.

Astrazeneca Pharma India Ltd has declared a 1200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1200%<BR>- Amount per share: 24<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.24%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 48.19%, with a dividend return of 0%, resulting in a total return of 48.19%.<BR><BR>Over the past year, the price return was 58.09%, with a dividend return of 0.38%, leading to a total return of 58.47%.<BR><BR>In the 2-year period, the price return was 181.37%, with a dividend return of 1.10%, culminating in a total return of 182.47%.<BR><BR>For the 3-year period, the price return was 232.0%, with a dividend return of 1.77%, resulting in a total return of 233.77%.<BR><BR>In the last 4 years, the price return was 158.33%, with a dividend return of 1.37%, leading to a total return of 159.7%.<BR><BR>Over the past 5 years, the price return was 208.87%, with a dividend return of 1.47%, culminating in a total return of 210.34%.<BR><BR>Overall, Astrazeneca Pharma India Ltd has declared a significant dividend, and the total returns across various periods indicate strong price appreciation, particularly over longer time frames, despite relatively low dividend returns in the short term.

Who are the peers of the Astrazeneca Phar?

Astrazeneca Phar's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Jubilant Pharmo, Caplin Point Lab, Natco Pharma, and Sai Life. Astrazeneca Phar has a 1-year return of 52.64%, with peers like Jubilant Pharmo showing the highest return at 69.21%.

Peers: The peers of Astrazeneca Phar are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Jubilant Pharmo, Caplin Point Lab, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, Caplin Point Lab, Natco Pharma, and the rest. Below Average growth is noted for Divi's Lab., Torrent Pharma, Astrazeneca Phar, Jubilant Pharmo, and the rest, while Excellent growth is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Astrazeneca Phar, Concord Biotech, Caplin Point Lab, Natco Pharma, and the rest, while Average capital structure is found at Jubilant Pharmo.<BR><BR>Return Snapshot: Jubilant Pharmo has the highest 1-year return at 69.21%, while Natco Pharma has the lowest at -13.51%. Astrazeneca Phar's 1-year return is 52.64%, which is significantly higher than Natco Pharma's but lower than Jubilant Pharmo's. Additionally, the peers with negative six-month returns include Concord Biotech, Natco Pharma, and Jubilant Pharmo.

Is Astrazeneca Phar overvalued or undervalued?

As of March 31, 2020, Astrazeneca Phar is considered very expensive with a PE ratio of 120.70, significantly higher than peers like Sun Pharma and Divi's Lab, indicating overvaluation despite strong stock performance.

As of 31 March 2020, Astrazeneca Phar's valuation grade moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued, with a PE ratio of 120.70, an EV to EBITDA ratio of 94.10, and a PEG ratio of 3.45. These ratios highlight a premium valuation compared to its peers, such as Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, with a PE ratio of 79.33.<BR><BR>The peer comparison further emphasizes Astrazeneca Phar's elevated valuation, as it stands out with its very expensive classification against a backdrop of peers that are either expensive or attractive. Additionally, the company's strong performance in stock returns, significantly outpacing the Sensex over various timeframes, reinforces the notion of overvaluation, as investors may be pricing in future growth that may not be sustainable at current levels.

What does Astrazeneca Phar do?

AstraZeneca Pharma India Limited manufactures, distributes, and markets pharmaceutical products, reporting net sales of ₹4,805 Cr and a net profit of ₹582 Cr for the quarter ending March 2025. It has a market cap of ₹23,391 Cr and key metrics include a P/E ratio of 114.00 and a return on equity of 28.39%.

Overview: <BR>AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Large Cap company.<BR><BR>History: <BR>AstraZeneca Pharma India Ltd was incorporated on July 11, 1979. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 4,805 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 582 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 23,391 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 114.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.70 <BR>Return on Equity: 28.39% <BR>Price to Book: 32.23<BR><BR>Contact Details: <BR>Address: Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road Bangalore Karnataka : 560045 <BR>Tel: 91-080-67748000 <BR>Email: comp.secy@astrazeneca.com <BR>Website: http://www.astrazeneca.in

How big is Astrazeneca Phar?

As of 24th July, Astrazeneca Pharma India Ltd has a market capitalization of 22,450.00 Cr, with recent net sales of 1,716.29 Cr and a net profit of 115.74 Cr.

As of 24th July, Astrazeneca Pharma India Ltd has a market capitalization of 22,450.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,716.29 Cr and a Net Profit of 115.74 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 711.92 Cr and Total Assets of 1,056.78 Cr.

Are Astrazeneca Phar latest results good or bad?

AstraZeneca Pharma's latest results show strong revenue growth of 35.81% year-on-year, reaching ₹526.31 crores in Q2 FY26. However, a 4.15% decline in net profit and a drop in operating margin raise concerns about profitability and cost pressures.

AstraZeneca Pharma's latest results present a mixed picture. On one hand, the company reported a strong year-on-year revenue growth of 35.81%, with net sales reaching ₹526.31 crores in Q2 FY26. This marks a continuation of their growth trend, as they have experienced sequential growth over the last seven quarters. However, there are concerns regarding profitability, as net profit declined by 4.15% quarter-on-quarter to ₹55.83 crores, and the operating margin fell to 15.41%, down 257 basis points from the previous quarter.<BR><BR>While the revenue growth is impressive and indicates strong demand dynamics, the decline in net profit and operating margin suggests that the company is facing cost pressures that could impact its profitability moving forward. Additionally, the stock has retreated in recent trading, reflecting investor concerns about the sustainability of these margins despite the robust top-line performance.<BR><BR>Overall, while AstraZeneca Pharma is showing strong revenue growth, the decline in profitability metrics raises questions about its near-term financial health, making the results somewhat concerning.

Should I buy, sell or hold Astrazeneca Phar?

How has been the historical performance of Astrazeneca Phar?

Astrazeneca Phar has shown significant growth in net sales, reaching 1,716.29 Cr in March 2025, up from 1,002.97 Cr in March 2023, despite a decline in profit margins and earnings per share. Total assets and liabilities increased to 1,476.56 Cr, while cash and cash equivalents rose to 536.70 Cr, indicating improved cash flow.

Answer:<BR>The historical performance of Astrazeneca Phar shows a significant growth trend in net sales and profits over the years, with net sales reaching 1,716.29 Cr in March 2025, up from 1,295.53 Cr in March 2024 and 1,002.97 Cr in March 2023. The total operating income followed a similar trajectory, increasing to 1,716.29 Cr in March 2025 from 1,295.53 Cr in March 2024. However, total expenditure also rose to 1,462.32 Cr in March 2025, compared to 1,111.08 Cr in March 2024, leading to an operating profit of 294.60 Cr in March 2025, up from 219.25 Cr in March 2024. Profit before tax decreased to 156.36 Cr in March 2025 from 219.54 Cr in March 2024, while profit after tax was 115.74 Cr in March 2025, down from 161.51 Cr in March 2024. The earnings per share (EPS) also saw a decline to 46.3 in March 2025 from 64.6 in March 2024. <BR><BR>In terms of assets and liabilities, total assets increased to 1,476.56 Cr in March 2025 from 1,056.78 Cr in March 2024, while total liabilities also rose to 1,476.56 Cr in March 2025 from 1,056.78 Cr in March 2024. The company maintained a strong cash position, with cash and cash equivalents rising to 536.70 Cr in March 2025 from 505.84 Cr in March 2024. The net cash inflow for March 2025 was 30.00 Cr, compared to 5.00 Cr in March 2024, indicating improved cash flow from operations. Overall, Astrazeneca Phar has demonstrated robust growth in sales and assets, despite fluctuations in profit margins and earnings per share.<BR><BR>Breakdown:<BR>Astrazeneca Phar has shown a strong upward trend in net sales, which increased from 1,002.97 Cr in March 2023 to 1,716.29 Cr in March 2025. This growth in revenue has been accompanied by a rise in total operating income, which reached 1,716.29 Cr in March 2025. However, the total expenditure also increased significantly, leading to an operating profit of 294.60 Cr in March 2025, a rise from 219.25 Cr in March 2024. Despite this, profit before tax saw a decline to 156.36 Cr in March 2025, down from 219.54 Cr in the previous year, and profit after tax also decreased to 115.74 Cr. The earnings per share reflected this trend, dropping to 46.3 in March 2025 from 64.6 in March 2024. On the balance sheet, total assets grew to 1,476.56 Cr in March 2025, while total liabilities matched this figure, indicating a balanced growth in both assets and liabilities. The company maintained a healthy cash position, with cash and cash equivalents increasing to 536.70 Cr, and a net cash inflow of 30.00 Cr in March 2025 suggests improved operational cash flow.

Is Astrazeneca Phar technically bullish or bearish?

As of November 7, 2025, the trend is mildly bullish, supported by positive MACD readings and moving averages, despite mixed signals from the KST and recent price declines, with strong long-term returns over 3 and 5 years.

As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by weekly and monthly MACD readings indicating bullish momentum. The Bollinger Bands and moving averages also reflect a mildly bullish outlook on the daily time frame. However, the KST shows a mixed signal with a bullish weekly but mildly bearish monthly reading. The Dow Theory aligns with a mildly bullish stance on both weekly and monthly charts. Despite recent price declines, the longer-term returns remain strong, particularly over 3 years and 5 years, indicating resilience in the stock.

Which are the latest news on Astrazeneca Phar?

Why is Astrazeneca Phar falling/rising?

As of 04-Dec, Astrazeneca Pharma India Ltd's stock price is rising to 9,159.00, driven by strong management efficiency, positive quarterly results, and consistent historical returns. Despite a decline in investor participation, the stock remains liquid and has outperformed the benchmark Sensex.

As of 04-Dec, Astrazeneca Pharma India Ltd's stock price is rising, currently at 9,159.00, reflecting an increase of 70.0 (0.77%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed the benchmark Sensex by 0.48% today, indicating strong relative performance in the market. Additionally, the company has demonstrated high management efficiency, evidenced by a return on equity (ROE) of 21.62% and a low debt-to-equity ratio of 0 times, which suggests financial stability.<BR><BR>Moreover, Astrazeneca has reported positive results for the last four consecutive quarters, with significant growth in operating cash flow and profit after tax, which has increased by 35.70% in the latest six months. The stock has also shown consistent returns over the past three years, achieving a remarkable 37.32% return in the last year alone, outperforming the BSE500 in each of the last three annual periods.<BR><BR>Despite a decline in investor participation, with a 59.23% drop in delivery volume compared to the five-day average, the stock remains liquid enough for trading. The current price movement reflects a combination of strong financial performance and historical returns, contributing to the stock's rise.